Abbott Laboratories (ABT) Q4 2025 Earnings Analysis
Nutritional No-Go as Abbott's Shares Take a 10% Dive
Key Takeaways
Abbott Laboratories (ABT) reported Q4 2025 earnings with revenue of $11.5B, representing a +4.4% year-over-year change. The stock moved -10.0% on earnings day.
The bull case: A broad, innovation-rich MedTech and diagnostics portfolio, reinforced by the Exact Sciences acquisition and durable CGM/EP/structural heart growth, supports high-single-digit sales, steady margin expansion, and consistent double-digit EPS growth.
The bear case: Execution risk around the nutrition reset, China/VBP and macro uncertainties, and integration plus dilution from Exact Sciences could pressure Abbott’s top-line trajectory and constrain the company’s ability to sustain its targeted margin and EPS growth algorithm.
Financial Highlights
- Revenue: $11.5B (+4.4% YoY)
- Gross Profit: $6.5B (57.0% margin, +6.0% YoY)
- Operating Income: $2.3B (19.6% margin, +1.5% YoY)
- Net Income: $1.8B
- TTM Revenue: $44.3B
Stock Performance
- Earnings Day Move: -10.0%
- Year-to-Date: -7.2%
- 1-Year Return: -14.6%
- vs. S&P 500 (since earnings): -16.1%
- vs. Nasdaq (since earnings): -15.0%
View live ABT data, AI chat, and interactive debates on Calypso →
What Management Said
Here are the key debates and direct quotes from Abbott Laboratories's Q4 2025 earnings call:
Nutrition Reset, 2026 Guide Cut, and H1/H2 Growth Cadence
Sentiment: Positive
"So today, we guided the midpoint at 7% on the top line, 10% on the bottom. So the midpoint here is half a percent lower than what was consensus. But other than that, nothing's really changed... So the half-point change on the top line is, as you pointed out, really the change in the near-term outlook, I'd say, of our nutrition business." — Robert Ford
"We began implementing price promotion initiatives that are going to help invigorate growth... we'll have a couple of quarters here where growth in nutrition is going to be challenged. And then in the second half, we'll return to positive growth... I think it's about a six-month process here of reshifting that, and that's really what's creating... this first half, second half dynamic in our growth forecast." — Robert Ford
Electrophysiology (EP) Portfolio and PFA Strategy vs Competition
Sentiment: Positive
"If you go back three years, David, there was a lot of concern about our franchise... that was going to, you know, be flat or even negative because we didn't have a PFA catheter... over the last couple of years, even without PFA products, we've been able to actually sustain our double-digit growth rates, you know, twenty-four and twenty-twenty-five without a PFA catheter." — Robert Ford
"I don't think that there is a company right now that's better positioned in terms of completeness of the portfolio than what we have... we've got both RF and PFA products... and on top of that, we've got an LAA device, which I would say is becoming pretty clear that if you want to be a leader in this space, you can't just look at having a PFA catheter... I expect that we should grow at least in line with the market... mid to high teens." — Robert Ford
CGM / Diabetes Growth Durability and Non‑Insulin Type 2 Reimbursement Upside
Sentiment: Positive
"I don't consider growing a billion dollars every single year and doing it four years in a row to be slowing down here, Robbie... I think the math will work out to what you just kind of highlighted there, in the kind of low teens. But I think there's still a lot of opportunity for penetration... we're far away from being from the seventh inning on this one." — Robert Ford
"You got about 6 million SGLT2 users in The US... only about a million of those six are on CGMs. So I think there's going to be an opportunity here also to kind of create market expansion with this product... I'm not baking [non‑insulin reimbursement] into my guidance. But, you know, I can tell you we will be 150% ready to execute... if it happened next week, I'd tell you they'd be prepared." — Robert Ford
Margin Expansion Sustainability and EPS Algorithm
Sentiment: Positive
"We continue to look at a 50 to 70 basis point improvement in operating margins every year, and that's kind of what we've got built into this and fully expect we'll do that through both gross margin expansion as we've done, but continue to gain leverage in the P&L where appropriate." — Philip Boudreau
"We've always targeted high single digits and double-digit, high single-digit top line, double-digit bottom line. That's our investment identity, and we've kind of followed through with that... having that flow through down to the bottom line, making investments in the areas that we need to, and nice gross margin and op margin profile expansion too." — Robert Ford
Exact Sciences Acquisition, Capital Allocation, and MCED Upside
Sentiment: Positive
"I feel good about us closing Exact Sciences... we're going to be adding another high-growth vertical with Exact Sciences... add on, you know, $3 billion plus business growing 15% a lot of growth opportunities for us." — Robert Ford
"Post-close, our gross debt to EBITDA ratio will be around 2.7 times. So to your point, we still have plenty of capacity... my focus right now is integration, closing Exact Sciences integration... I largely agree with your report. I think [multicancer early detection] is going to be another great opportunity for us... I think that if that becomes the case, I think your forecast is way under cold even on the upper side." — Robert Ford
Bull Case
A broad, innovation-rich MedTech and diagnostics portfolio, reinforced by the Exact Sciences acquisition and durable CGM/EP/structural heart growth, supports high-single-digit sales, steady margin expansion, and consistent double-digit EPS growth.
Bear Case
Execution risk around the nutrition reset, China/VBP and macro uncertainties, and integration plus dilution from Exact Sciences could pressure Abbott’s top-line trajectory and constrain the company’s ability to sustain its targeted margin and EPS growth algorithm.
Looking Ahead
Investors will be closely watching Abbott Laboratories's next quarterly report for continued execution, particularly around nutrition Reset, 2026 Guide Cut, and H1/H2 Growth Cadence. With operating margins at 19.6%, margin trends will remain a focal point. The market's negative earnings-day reaction signals that investors need to see stronger execution, and the next earnings report will be a key catalyst for the stock.
Frequently Asked Questions
What was Abbott Laboratories's revenue in Q4 2025?
Abbott Laboratories reported Q4 2025 revenue of $11.5B, representing a +4.4% year-over-year change.
Did Abbott Laboratories beat earnings expectations in Q4 2025?
The stock declined -10.0% on earnings day, suggesting the results fell short of market expectations. The current bull case centers on: A broad, innovation-rich MedTech and diagnostics portfolio, reinforced by the Exact Sciences acquisition and durable CGM/EP/structural heart growth, supports high-single-digit sales, steady margin expansion, and consistent double-digit EPS growth.
What is the bull case for ABT stock?
The bull case for ABT centers on: A broad, innovation-rich MedTech and diagnostics portfolio, reinforced by the Exact Sciences acquisition and durable CGM/EP/structural heart growth, supports high-single-digit sales, steady margin expansion, and consistent double-digit EPS growth.
What is the bear case for ABT stock?
The bear case for ABT centers on: Execution risk around the nutrition reset, China/VBP and macro uncertainties, and integration plus dilution from Exact Sciences could pressure Abbott’s top-line trajectory and constrain the company’s ability to sustain its targeted margin and EPS growth algorithm.
How has ABT stock performed since its Q4 2025 earnings?
ABT moved -10.0% on the day of its Q4 2025 earnings report, underperforming the S&P 500 by +16.1% since earnings. Year-to-date, the stock has returned -7.2%.
Related Earnings Reports
Browse all 400+ earnings reports →
Learn More
Analyze ABT in Real Time
This is a static snapshot. For live financial data, AI-powered chat, and interactive earnings debates for Abbott Laboratories and 400+ other stocks, explore the full platform.
Calypso is an AI-powered equity research platform used by investment teams to cut earnings research time by over 80%.